
|Articles|June 3, 2014
Comparing Toxicities and Patient-Stated Preference in the SWOG S0307 Trial
Author(s)Julie R. Gralow, MD
Julie R. Gralow, MD, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.
Advertisement
Julie R. Gralow, MD, director, Breast Medical Oncology, Seattle Cancer Care Alliance, discusses an analysis of the phase III SWOG S0307 trial comparing toxicities and patient-stated preference for oral versus intravenous delivery of bisphosphonates as adjuvant therapy in primary breast cancer.
<<<
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Alpelisib/Fulvestrant Improves PFS in Post-CDK4/6 HR+/HER2- Breast Cancer
2
Gedatolisib Improves PFS in HR+/HER2-/PIK3CA-WT Advanced Breast Cancer
3
FDA Approves Niraparib/Abiraterone Combo for BRCA2-Mutated mCSPC
4
Nadunolimab Misses Efficacy Mark in TNBC, Despite Strong OS
5









































